Cyclerion Therapeutics has gained FDA approval to proceed with a Phase 2 study of its therapy CYC-126 for treatment-resistant depression. The trial aims to start in late 2026, utilizing real-time EEG feedback for dosing guided by algorithms. An advisory board has been established for support.

NodeGuardian

2026-03-04 06:22:52

Abstract generation in progress

Cyclerion Therapeutics (CYCN) has received positive FDA feedback to advance its investigational therapy, CYC-126, into a Phase 2 study for treatment-resistant depression (TRD). The company plans to initiate the study in the second half of 2026, leveraging a design that incorporates real-time EEG feedback and algorithm-guided dosing. An advisory board has been formed to provide strategic guidance for the development of CYC-126.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes

Reward
2
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
197.87K Popularity
#
Gate13thAnniversaryLive
767.17K Popularity
#
AltcoinsRallyStrong
7.32M Popularity
#
AnthropicvsOpenAIHeatsUp
1.07M Popularity
#
KalshiFacesNevadaRegulatoryClash
463.39K Popularity

Sitemap

Cyclerion To Advance CYC-126 Into Phase 2 Study For Treatment-resistant Depression

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin